Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Target discovery for new antitubercular drugs using a large dataset of growth inhibitors from PubChem.

Goldman RC.

Infect Disord Drug Targets. 2018 Dec 5. doi: 10.2174/1871526519666181205163810. [Epub ahead of print]

PMID:
30520384
2.

Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Goldman RC.

Tuberculosis (Edinb). 2013 Nov;93(6):569-88. doi: 10.1016/j.tube.2013.09.003. Epub 2013 Sep 18. Review.

PMID:
24119636
3.

Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosis.

Vicente E, Villar R, Pérez-Silanes S, Aldana I, Goldman RC, Mong A.

Infect Disord Drug Targets. 2011 Apr;11(2):196-204. Review.

4.

Maximizing bactericidal activity with combinations of bioreduced drugs.

Goldman RC.

Future Med Chem. 2010 Aug;2(8):1253-71. doi: 10.4155/fmc.10.215.

PMID:
21426017
5.

Antituberculosis activity of the molecular libraries screening center network library.

Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Reynolds RC, Secrist JA 3rd, Sosa MI, White EL, Zhang W.

Tuberculosis (Edinb). 2009 Sep;89(5):354-63. doi: 10.1016/j.tube.2009.07.006. Epub 2009 Sep 26.

6.

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist JA 3rd, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL.

Tuberculosis (Edinb). 2009 Sep;89(5):334-53. doi: 10.1016/j.tube.2009.05.008. Epub 2009 Sep 15.

7.

Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Goldman RC, Laughon BE.

Tuberculosis (Edinb). 2009 Sep;89(5):331-3. doi: 10.1016/j.tube.2009.07.007. Epub 2009 Aug 28.

8.

Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.

Vicente E, Villar R, Burguete A, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

Antimicrob Agents Chemother. 2008 Sep;52(9):3321-6. doi: 10.1128/AAC.00379-08. Epub 2008 Jul 14.

9.

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Villar R, Vicente E, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

J Antimicrob Chemother. 2008 Sep;62(3):547-54. doi: 10.1093/jac/dkn214. Epub 2008 May 23.

10.

Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility.

Goldman RC, Laughon BE, Reynolds RC, Secrist JA 3rd, Maddry JA, Guié MA, Poffenberger AC, Kwong CA, Ananthan S.

Infect Disord Drug Targets. 2007 Jun;7(2):92-104.

PMID:
17970221
11.

The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.

Goldman RC, Plumley KV, Laughon BE.

Infect Disord Drug Targets. 2007 Jun;7(2):73-91. Review.

PMID:
17970220
12.

The macrolide-bacterium interaction and its biological basis.

Goldman RC, Scaglione F.

Curr Drug Targets Infect Disord. 2004 Sep;4(3):241-60. Review.

PMID:
15379734
13.

In vivo characterization of A-192411: a novel fungicidal lipopeptide (II).

Meulbroek JA, Nilius AM, Li Q, Wang W, Hasvold L, Steiner B, Dickman DA, Ding H, Frost D, Goldman RC, Lartey P, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):495-7.

PMID:
12565958
14.

Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I).

Wang W, Li Q, Hasvold L, Steiner B, Dickman DA, Ding H, Clairborne A, Chen HJ, Frost D, Goldman RC, Marsh K, Hui YH, Cox B, Nilius A, Balli D, Lartey P, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):489-93.

PMID:
12565957
15.

Infectious disorders. Introduction.

Goldman RC.

Curr Drug Targets Infect Disord. 2001 May;1(1):2p. No abstract available.

PMID:
12455228
16.

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.

Printsevskaya SS, Pavlov AY, Olsufyeva EN, Mirchink EP, Isakova EB, Reznikova MI, Goldman RC, Branstrom AA, Baizman ER, Longley CB, Sztaricskai F, Batta G, Preobrazhenskaya MN.

J Med Chem. 2002 Mar 14;45(6):1340-7.

PMID:
11882003
17.

Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin.

Eggert US, Ruiz N, Falcone BV, Branstrom AA, Goldman RC, Silhavy TJ, Kahne D.

Science. 2001 Oct 12;294(5541):361-4. Epub 2001 Aug 23.

18.

Synthesis of hydrophobic N'-mono and N',N"-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis.

Pavlov AY, Miroshnikova OV, Printsevskaya SS, Olsufyeva EN, Preobrazhenskaya MN, Goldman RC, Branstrom AA, Baizman ER, Longley CB.

J Antibiot (Tokyo). 2001 May;54(5):455-9.

19.

Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase.

Baizman ER, Branstrom AA, Longley CB, Allanson N, Sofia MJ, Gange D, Goldman RC.

Microbiology. 2000 Dec;146 Pt 12:3129-40.

PMID:
11101671
20.

Differential antibacterial activity of moenomycin analogues on gram-positive bacteria.

Goldman RC, Baizman ER, Branstrom AA, Longley CB.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2251-4.

PMID:
11055331
21.

In situ assay for identifying inhibitors of bacterial transglycosylase.

Branstrom AA, Midha S, Goldman RC.

FEMS Microbiol Lett. 2000 Oct 15;191(2):187-90.

22.

Antifungal rapamycin analogues with reduced immunosuppressive activity.

Dickman DA, Ding H, Li Q, Nilius AM, Balli DJ, Ballaron SJ, Trevillyan JM, Smith ML, Seif LS, Kim K, Sarthy A, Goldman RC, Plattner JJ, Bennani YL.

Bioorg Med Chem Lett. 2000 Jul 3;10(13):1405-8.

PMID:
10888319
23.

Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis.

Goldman RC, Gange D.

Curr Med Chem. 2000 Aug;7(8):801-20. Review.

PMID:
10828288
24.
25.

Targeting cell wall synthesis and assembly in microbes: similarities and contrasts between bacteria and fungi.

Goldman RC, Branstrom A.

Curr Pharm Des. 1999 Jul;5(7):473-501. Review.

PMID:
10438893
26.

Domain structure analysis of elongation factor-3 from Saccharomyces cerevisiae by limited proteolysis and differential scanning calorimetry.

Ladror US, Egan DA, Snyder SW, Capobianco JO, Goldman RC, Dorwin SA, Johnson RW, Edalji R, Sarthy AV, McGonigal T, Walter KA, Holzman TF.

Protein Sci. 1998 Dec;7(12):2595-601.

27.

Identification and kinetic analysis of a functional homolog of elongation factor 3, YEF3 in Saccharomyces cerevisiae.

Sarthy AV, McGonigal T, Capobianco JO, Schmidt M, Green SR, Moehle CM, Goldman RC.

Yeast. 1998 Feb;14(3):239-53. Erratum in: Yeast 1998 Jun 15;14(8):792.

28.

Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis.

Doucet-Populaire F, Capobianco JO, Zakula D, Jarlier V, Goldman RC.

J Antimicrob Chemother. 1998 Feb;41(2):179-87.

PMID:
9533459
29.

Cellular accumulation, localization, and activity of a synthetic cyclopeptamine in fungi.

Capobianco JO, Zakula D, Frost DJ, Goldman RC, Li L, Klein LL, Lartey PA.

Antimicrob Agents Chemother. 1998 Feb;42(2):389-93.

30.

High-level overexpression of yeast elongation factor 3 and detailed kinetic analysis using a coupled spectrophotometric assay.

Sarthy AV, McGonigal T, Capobianco JO, Holzman TH, Walter KA, Egan DA, Goldman RC.

Anal Biochem. 1997 Dec 15;254(2):288-90. No abstract available.

PMID:
9417791
31.

Characterization of a lipopeptide-resistant strain of Candida albicans.

Frost DJ, Knapp M, Brandt K, Shadron A, Goldman RC.

Can J Microbiol. 1997 Feb;43(2):122-8.

PMID:
9090103
32.

Novel antifungal agents which inhibit lanosterol 14alpha-demethylase in Candida albicans CCH442.

Zakula D, Capobianco JO, Goldman RC.

J Antimicrob Chemother. 1997 Feb;39(2):261-4. Erratum in: J Antimicrob Chemother 1998 Jun;41(6):671.

PMID:
9069550
33.

Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-beta-glucosyltransferase.

Sarthy AV, McGonigal T, Coen M, Frost DJ, Meulbroek JA, Goldman RC.

Microbiology. 1997 Feb;143 ( Pt 2):367-76.

PMID:
9043114
34.

Inhibition of 2,3-oxidosqualene-lanosterol cyclase in Candida albicans by pyridinium ion-based inhibitors.

Goldman RC, Zakula D, Capobianco JO, Sharpe BA, Griffin JH.

Antimicrob Agents Chemother. 1996 Apr;40(4):1044-7.

35.

Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).

Thornton BP, Vĕtvicka V, Pitman M, Goldman RC, Ross GD.

J Immunol. 1996 Feb 1;156(3):1235-46.

PMID:
8558003
36.

Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents.

Rose IC, Sharpe BA, Lee RC, Griffin JH, Capobianco JO, Zakula D, Goldman RC.

Bioorg Med Chem. 1996 Jan;4(1):97-103.

PMID:
8689245
37.

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.

Goldman RC, Frost DJ, Capobianco JO, Kadam S, Rasmussen RR, Abad-Zapatero C.

Infect Agents Dis. 1995 Dec;4(4):228-47. Review.

PMID:
8665087
38.

Kinetics of beta-1,3 glucan interaction at the donor and acceptor sites of the fungal glucosyltransferase encoded by the BGL2 gene.

Goldman RC, Sullivan PA, Zakula D, Capobianco JO.

Eur J Biochem. 1995 Jan 15;227(1-2):372-8.

39.

Synthesis of yeast cell wall glucan and evidence for glucan metabolism in a Saccharomyces cerevisiae whole cell system.

Coen ML, Lerner CG, Capobianco JO, Goldman RC.

Microbiology. 1994 Sep;140 ( Pt 9):2229-37.

PMID:
7952174
40.

Macrolide transport in Escherichia coli strains having normal and altered OmpC and/or OmpF porins.

Capobianco JO, Goldman RC.

Int J Antimicrob Agents. 1994 Aug;4(3):183-9.

PMID:
18611609
41.

Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes.

Goldman RC, Zakula D, Flamm R, Beyer J, Capobianco J.

Antimicrob Agents Chemother. 1994 Jul;38(7):1496-500.

42.

Stimuli that induce production of Candida albicans extracellular aspartyl proteinase.

Lerner CG, Goldman RC.

J Gen Microbiol. 1993 Jul;139(7):1643-51.

PMID:
7690395
43.

Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action.

Capobianco JO, Zakula D, Coen ML, Goldman RC.

Biochem Biophys Res Commun. 1993 Feb 15;190(3):1037-44.

PMID:
8439305
44.

A non-azole inhibitor of lanosterol 14 alpha-methyl demethylase in Candida albicans.

Capobianco JO, Doran CC, Goldman RC, De B.

J Antimicrob Chemother. 1992 Dec;30(6):781-90.

PMID:
1289352
46.

Inhibition of lipopolysaccharide synthesis in Agrobacterium tumefaciens and Aeromonas salmonicida.

Goldman RC, Capobianco JO, Doran CC, Matthysse AG.

J Gen Microbiol. 1992 Jul;138(7):1527-33.

PMID:
1324975
47.

The future of antifungal drug research.

Goldman RC.

G Ital Chemioter. 1991 Jan-Dec;38(1-3):71-3. No abstract available.

PMID:
1365616
48.
50.

Mechanism of O-antigen distribution in lipopolysaccharide.

Goldman RC, Hunt F.

J Bacteriol. 1990 Sep;172(9):5352-9.

Supplemental Content

Loading ...
Support Center